Endari Sickle Cell Therapy Now Under Review in Saudi Arabia

Endari Sickle Cell Therapy Now Under Review in Saudi Arabia

295436

Endari Sickle Cell Therapy Now Under Review in Saudi Arabia

The Saudi Food and Drug Authority (SFDA), in Saudi Arabia, will review Emmaus Life Sciences’ application for the approval of its oral medication Endari (L-glutamine) for treating sickle cell disease (SCD). Given that the SFDA’s review process typically takes 12 to 18 months, a decision is not expected before mid- to late-2022. Meanwhile, Endari will be available to eligible SCD patients in the Kingdom of Saudi Arabia on an early access basis to address an unmet…

You must be logged in to read/download the full post.